Clinical-stage radiopharmaceutical company Clarity Pharmaceuticals (ASX:CU6) has announced positive results from the diagnostic Phase 2 DISCO study with 64Cu-SARTATE in patients with known or suspected neuroendocrine tumours. …
Latest Video
New Stories
-
Hospital pharmacists use Rare Cancers Awareness Day to call for reform
June 27, 2025 - - Latest News -
MedAdvisor progressing review, including the potential sale of ANZ business
June 27, 2025 - - Latest News -
Mark Butler retains position on critical Cabinet committee
June 26, 2025 - - Latest News -
New Zealand to streamline access to ADHD treatments
June 26, 2025 - - Latest News -
CLEO strengthens FDA submission following Access to globally recognised Biobank
June 25, 2025 - - Australian Biotech -
Leukaemia Foundation calls for urgent action to address diagnosis and treatment gaps
June 25, 2025 - - Latest News -
QBiotics' candidate produces strong efficacy result in soft tissue sarcoma trial
June 25, 2025 - - Latest News